Generics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists

Documenti analoghi

• Diagnoses of Multiple Sclerosis and Related Disorders and Disease‐Modifying Therapies: A Comparison of the Danish Multiple Sclerosis Registry With Other Danish Health Registries
  di: Hanna Joensen, et al.
  Pubblicazione: (2026)
• De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study
  di: Frederik Elberling, et al.
  Pubblicazione: (2025)
• Biosimilars for Australian Dermatologists
  di: Grace X. Li, et al.
  Pubblicazione: (2025)
• Chronicles of progress: Celebrating 40 years of scientific excellence in diabetes
  di: Paolo Pozzilli
  Pubblicazione: (2024)
• Scaling Graph Neural Networks to Large Proteins
  di: Airas, Justin, et al.
  Pubblicazione: (2024)